How Gilead finally spent its money
Bio Pharma Dive
NOVEMBER 24, 2020
This year, the biotech spent about $27 billion trying to become a leader in cancer research. Executives who spoke to BioPharma Dive said there's still work to be done.
Sat.Nov 21, 2020 - Fri.Nov 27, 2020
347 
Health misinformation online abounds
World of DTC Marketing
NOVEMBER 24, 2020
SUMMARY : In a 2019 Pew Research Center poll, more Americans said they consider made-up news a bigger problem than terrorism, illegal immigration, racism, and sexism. And 68% said disinformation greatly impacts people’s confidence in government institutions. No matter the form, inaccurate health information is a danger to public health. While psychological factors leave people unguarded against misinformation, people in the U.S. are particularly vulnerable to health misinformation because the l
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NHS to trial innovative cancer blood test
Pharma Times
NOVEMBER 27, 2020
It is hoped that the test will help detect cancer at a much earlier stage
McKinsey Proposed Paying Pharmacy Companies Rebates for OxyContin Overdoses
NY Times
NOVEMBER 27, 2020
Court filings reveal consultants’ talk of a records purge during the opioid crisis, and shed new light on sales advice given to the billionaire Sackler family and their drug company, Purdue Pharma.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AstraZeneca, Oxford coronavirus vaccine prevents COVID-19, though study results raise questions
Bio Pharma Dive
NOVEMBER 23, 2020
Data from two late-stage trials showed the shot to be, on average, 70% effective against COVID-19, an encouraging finding. The lower dose tested, however, outperformed a higher dose.
So much for pharma earning trust back
World of DTC Marketing
NOVEMBER 27, 2020
SUMMARY: Business by press release has made pharma executives a lot of money but we still haven’t seen any over reviewed data on COVID 19 vaccines. A report released Thursday by the University of California at Los Angeles researchers said that 66 percent of Los Angeles health-care workers who responded to an online questionnaire (not a randomized sample) said they would delay taking a vaccine.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Politics, Science and the Remarkable Race for a Coronavirus Vaccine
NY Times
NOVEMBER 21, 2020
The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, with the stakes as high as they could get.
Merck, expanding coronavirus work, buys a small biotech and its COVID-19 drug
Bio Pharma Dive
NOVEMBER 23, 2020
The large drugmaker will pay $425 million to acquire OncoImmune, which is developing a treatment for severe coronavirus disease.
My thoughts this Thanksgiving
World of DTC Marketing
NOVEMBER 25, 2020
SUMMARY: This Thanksgiving, my thoughts turn to families who are going to have an empty seat at the table because of COVID-19. Over 2100 people died from COVID-19 yesterday as the void in leadership continues. Maybe I’m too empathetic, but these people are someone’s dad, father, son, or daughter, and many of these deaths could have been prevented if only we had leadership who put as much emphasis on prevention as they did on “fake news.” On Facebook, local newspaper feeds
SARS-CoV-2 Causes Heart Damage in 20% of People with Mild or No COVID-19 Symptoms
BioSpace
NOVEMBER 22, 2020
COVID-19 is a cardiac condition as much as it is a pulmonary or respiratory disease. This knowledge is so recent that it often is overlooked by non-cardiologists, according to physicians speaking at Demy-Colton Virtual Salon, “COVID-19: Surprising Cardiac Findings & Concern about the Potential Im.
Bill Gates, the Virus and the Quest to Vaccinate the World
NY Times
NOVEMBER 23, 2020
The billionaire is working with the W.H.O., drugmakers and nonprofits to defeat the coronavirus everywhere, including in the world’s poorest nations. Can they do it?
Amgen cuts Cytokinetics loose after heart drug disappointment
Bio Pharma Dive
NOVEMBER 23, 2020
The smaller biotech vowed to push forward, although the pill's inability to prevent heart failure death may complicate its plans to win approval.
Pfizer’s ad first step in restoring trust
World of DTC Marketing
NOVEMBER 23, 2020
SUMMARY: Pfizer’s ad in newspapers around the U.S. shows that they are ready to lead the fight against COVID-19 and in the process establish that their vaccine is safe and has been well tested. Pfizer ran an ad today that is superb. The ad, for it’s COVID-19 vaccine, has a headline that says “courage” and details that 43,661 people tested their vaccine and ends with “science will win” This ad send out a reassurance to vaccine skeptics who have come to believe
Symkevi/Kalydeco cleared for use in young CF patients
Pharma Times
NOVEMBER 27, 2020
The combination is the first available to treat the underlying cause of CF in this patient group.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Digital health player UpHealth swells with three-way merger
pharmaphorum
NOVEMBER 24, 2020
A merger involving two US digital health specialists and a blank cheque company has created a telemedicine player, called UpHealth, that is valued at more than $1.3 billion. The three-way deal combines UpHealth – which provides patient care management, telemedicine and digital pharmacy services and gives its name to the new group – with CloudBreak, which provides a video consultation platform for doctors and patients.
Alnylam wins US approval for its third rare disease drug
Bio Pharma Dive
NOVEMBER 24, 2020
The drug, now known as Oxlumo, is the first approved treatment for patients with a potentially life-threatening condition that can cause kidney failure. Like other Alnylam drugs, it comes at a six-figure list price.
Nonclinical Pulmonary Drug Delivery: Setting Up Your Inhalation Drug Study for Success
Camargo
NOVEMBER 24, 2020
Most are familiar with, know someone who uses, or take “pumps” themselves to prevent or relieve shortness of breath after an effort or during allergy season. Medicine has been delivered by inhalation for decades to treat human respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and airway infection.
Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)
Pharma Mirror
NOVEMBER 24, 2020
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NS
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Vertex gets EU okay to treat younger cystic fibrosis patients
pharmaphorum
NOVEMBER 27, 2020
A new EMA approval has expanded the use of Vertex Pharma’s exon-skipping cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light to use of Symkevi (tezacaftor/ivacaftor) with Vertex’ Kalydeco (ivacaftor) in patients ages six years and older who have two copies of the F508del mutation in the CFTR gene, or one F508del copy and one of 14 other so-called “minimal function” mutations in CFTR.
Biogen stocks up on Sage's brain drugs in $3B deal
Bio Pharma Dive
NOVEMBER 27, 2020
By teaming up with Sage, Biogen gets its hands on two drugs in mid- to late-stage testing for multiple types of depression and essential tremor.
EU to review Merck's targeted lung cancer drug
Pharma Times
NOVEMBER 27, 2020
Tepotinib could be the first treatment on the market for NSCLC in adults harbouring METex14 skipping alterations
FIP expert group issues advice for pharmacists on COVID-19 tests
Pharma Mirror
NOVEMBER 21, 2020
The Hague — To help pharmacists advise people on COVID-19 tests, the International Pharmaceutical Federation (FIP), has today issued a guidance document. The guidance has been produced by FIP’s SARS-CoV-2 Testing Working Group, which has evaluated the diagnostic testing methods and devices currently available. The document covers how different types of diagnostic test work and the interpretation of results.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
How the rare disease community has developed fertile ground for progress
pharmaphorum
NOVEMBER 27, 2020
Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an economic no-go area for pharma and biotech companies. That was among the discussion points during Fighting Rare Diseases – The Science, Economics and the Patients , a webinar hosted by o2h Group.
Giving the Gift of Time, FDA Approves First Treatment for Rare Childhood Aging Diseases
BioSpace
NOVEMBER 22, 2020
Eiger’s Zokinvy is the first-ever approved treatment for children with Huchinson-Gilford Progeria Syndrome and processing-deficient Progeroid Laminopathies.
Annual pharma R&D spending in UK climbed 6.9% in 2019
Pharma Times
NOVEMBER 23, 2020
R&D spending in the sector last year represents an eight-year high
UCB taps Medisafe in development of digital companion to support patient engagement
Pharma Mirror
NOVEMBER 21, 2020
Medisafe, a leading digital therapeutics company specializing in digital companions, has been selected by UCB to develop branded digital drug companions for its antiepileptic medications, with greater capabilities to expand across additional brands. The digital companions streamline support for patients to access financial assistance, patient diaries, and doctor discussion guides throughout their treatment journey.
3 steps for comprehensive patient collaboration
pharmaphorum
NOVEMBER 23, 2020
Janssen’s Daniel de Schryver tells us why it’s time to give patients a permanent seat at the table and improve health outcomes through patient-pharma dialogue. I’m struck by just how much we thrive when we share a common purpose; when – as a society, a group or a family unit – we work together to achieve the same goal. It’s no different in healthcare.
MIT Researchers Create AI that Detects COVID-19 Infections Through Cellphone-Recorded Coughs
XTalks
NOVEMBER 26, 2020
MIT researchers developed an algorithm that has correctly identified asymptomatic people with COVID-19 by the sound of their forced coughs using their smartphone devices. The researchers have found that asymptomatic people may differ from healthy people in the way that they cough. These differences are not identifiable by the human ear, but the researchers have developed an AI that can detect this difference.
GSK launches late-stage study of RSV vaccine in pregnant mothers
Pharma Times
NOVEMBER 25, 2020
Shot will be evaluated in pregnant mothers and their newborn infants
COVID-19 vaccine hope for older adults: following release of AstraZeneca, Pfizer, Moderna clinical trial data
BioPharma Reporter
NOVEMBER 23, 2020
Study data from leading COVID-19 vaccine candidates suggests they may be effective in older people.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Let's personalize your content